Modern Medicine
featured
The Epi-Pill offers another way to combat allergic reactions at a stable price, but it also presents a new set of challenges. » Read More
By: Robert Ferris
Zika can survive in a highly contagious form outside a host, such as on a table or counter. But common chemicals can kill it. » Read More |
By: Robert Ferris
Chinese scientists are first to inject a person with gene-edited cells using the CRISPR technique. This could be America's biotech Sputnik. » Read More |
CNBC's Meg Tirrell speaks with Alkermes Chairman & CEO Richard Pops at the Partnering for Cures conference about drug pricing, his company's new depression drug and the opioid epidemic. » Read More |
More
CNBC's Meg Tirrell speaks with Dr. Francis Collins, National Institutes of Health director, and Mike Milken, Milken Institute Chairman, about the future of medical research and the support for science in Washington D.C.
A hospital is bringing value to its patients inside the operating room and beyond
Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer, NBC News reports.
Last year the flu cost the economy billions of dollars. This season could be worse, since fewer people are opting for vaccinations.
These innovative companies are working on new methods to make chemotherapy safer, and more tolerable, for cancer patients in America.
A new drug being tested slows Alzheimer's by removing plaque buildup in the brain. It's hope for millions suffering from the disease.
Dominance in the genetic-sequencing market is causing Illumina's decline. A company can be too good and fast at exploiting new technology.
Researchers are working on opioids with all the painkilling power of current drugs but with less risk of addiction or overdose.
Bristol-Myers Squibb's approach to treating lung cancer will have a chance to redeem itself when new data comes out on Sunday.
A switch in health insurers is making a big difference for some employees at Activision Blizzard.
GoBabyGo modifies toys so that children with even the most severe mobility issues can use them. The idea grabbed Mattel's attention.
New non-invasive tests are helping doctors better diagnose what stage prostate cancer patients have so they can forgo risky biopsies.
Strains of bacteria resistant to antibiotics have been gaining strength and shifting the tide in their favor, a CDC official tells CNBC.
When we think about taking medicines, we imagine popping a pill, or receiving a shot. But a new approach would leverage the body's electrical signals.
Latest Special Reports
Covering the full set of tools and strategies for long-term investors: How to take everyday market fluctuations in stride, and when to know it’s time to take action or protect against a major economic shifts.
Take an in-depth look at the world of modern medicine - examining the treatments, companies and people making a difference in the way we treat illness and injuries today, and laying the foundation for the medical treatments of tomorrow.
Health Care
Health spending on privately insured people rose 4.6%, with much of it coming from drugs and medical services.
Hospitals that benefited likely will see a reversal of fortune and there are new risks for struggling insurers.
Juno Therapeutics shares shed 24 percent Wednesday after the biopharmaceutical company announced complications with its Phase II clinical trial of JCAR015.
Equipment and Services
The Epi-Pill offers a new way to combat allergic reactions at a stable price but also presents challenges.
Practo's Shashank ND explains how he's streamlined the process of tracking medical professionals and appointment bookings.
Last year the flu cost the economy billions. This season could be worse, since fewer people are opting for vaccinations.
Hospitals
Health spending on privately insured people rose 4.6%, with much of it coming from drugs and medical services.
Hospitals that benefited likely will see a reversal of fortune and there are new risks for struggling insurers.
But repealing and replacing Obamacare is going to be harder than Republicans think, Jay Angoff tells CNBC.
Health Care IT
Health spending on privately insured people rose 4.6%, with much of it coming from drugs and medical services.
CNBC's Rick Santelli and Robert Laszewski, Health Policy & Strategy Associates, discuss President-elect Donald Trump's health care policies.
Hospitals that benefited likely will see a reversal of fortune and there are new risks for struggling insurers.
Biotech and Pharma
Vamil Divan, Credit Suisse senior analyst, discusses Eli Lilly's failed Alzheimer's drug trial and the effect on its stock price.
Ronny Gal, Bernstein senior analyst, weighs in on Eli Lilly's failed Alzheimer's drug study results.
Health spending on privately insured people rose 4.6%, with much of it coming from drugs and medical services.
Technology
Smartphone operating profit in the third quarter reached $9 billion of which Apple took 91 percent of the share.
India’s ban on 500 and 1,000 rupee notes has opened up a new revenue stream for one Delhi-based start-up.
The Twitter account of the social media service's CEO Jack Dorsey was briefly suspended on Tuesday evening.
